CHILDRENS CANCER GROUP

儿童癌症已经取得了显著的进展，包括明显更有效的治疗，对这些疾病的生物学的洞察，对病因的更明确的定义，以及对这些疾病幸存者的结果的新的关注。这些进展在很大程度上是由合作的临床试验小组推动的。这笔赠款将促进明尼苏达大学的研究人员继续参与儿童癌症小组(CCG)进行的多机构合作治疗和非治疗研究。在过去的拨款周期中，明尼苏达州的调查人员一直站在所有这些场馆的前列，并准备在未来继续这种富有成效的关系。1997年，明尼苏达联盟在治疗试验(第一、第二和第三阶段)中登记了162名患者，此外，还登记了近100项非治疗性(生物学、流行病学)研究中的患者。强大的患者收益、数据管理、集团领导力和CCG出版物的作者身份相结合，使明尼苏达州在1995年、1996年和1997年在所有集团机构中排名第一。明尼苏达州的研究人员在流行病学和癌症控制、造血干细胞移植、急性淋巴细胞性白血病和急性髓系白血病、生物学和实验疗法方面继续发挥着强大的领导作用。在过去的拨款周期中，明尼苏达州的研究人员担任了14个小组治疗或科学委员会的主席，并在另外24个委员会担任副主席。明尼苏达州在团体出版物的第一作者方面一直处于领先地位。干细胞移植、流行病学和癌症控制、实验治疗学和生物学方面的机构研究已被应用于群体研究，所有这些领域的未来调查正在进行中。这笔赠款要求为对我们未来的集体活动至关重要的人员提供支持。它将确保在数据管理方面继续保持卓越，允许调查人员和其他关键人员出差参加小组会议，并为小组研究产生的病人应计费用提供所需资金。这笔资金将确保明尼苏达州调查人员在未来五年内继续在儿童癌症小组的各个方面发挥领导作用。

Dramatic gains have been made in childhood cancer including markedly more effective therapy, insights into the biology of these diseases, a clearer definition of etiologic factors, and a new focus on the outcomes of the survivors of these diseases. These gains have largely been facilitated by the cooperative clinical trials groups. This grant will facilitate the continued involvement of the investigators at the University of Minnesota in the multi-institutional cooperative therapeutic and non- therapeutic studies conducted by the Children's Cancer Group (CCG). Minnesota investigators have been at the forefront of all of these venues over the past grant cycle and are poised to continue this productive relationship into the future. In 1997, the Minnesota consortium registered 162 patients on therapeutic trials (phase I, II, and III) and, in addition, registered patients on almost 100 non-therapeutic (biology, epidemiology) studies. The combination of strong patient accrual, data management, group leadership, and authorship of CCG publications resulted in Minnesota being ranked first among all group institutions in 1995, 1996, and 1997. Minnesota investigators have continued strong leadership roles in Epidemiology and Cancer Control, Hematopoetic Stem Cell Transplantation, acute lymphoblastic and acute myeloid leukemia, biology, and experimental therapeutics. Over the past grant cycle, Minnesota investigators have chaired fourteen group therapeutic or scientific committees and served as vice-chairs on an additional twenty four. Minnesota has consistently led the group in first- authorship of group publications. Institutional research in stem cell transplantation, epidemiology and cancer control, experimental therapeutics, and biology has been applied to group studies and future investigations of all of these areas are under development. This grant requests support for the personnel critical to our future group activities. It will assure continued excellence in data management, allow travel by investigators and other key personnel to group meetings, and supply the funds needed for expenses generated by the accrual of patients to group studies. This funding will assure the continued leadership of Minnesota investigators in all aspects of the Children's Cancer Group over the coming five years.